ORPHA:37553
Andersen-Tawil syndrome
Also known as: Andersen syndrome · LQT7 · Long QT syndrome type 7
Publications
4,262
91.8th percentile
Trials
2
Interventional, condition-specific
Researchers
1,108
Distinct authors in sample
Gene link
KCNJ2
Definitive
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder characterized by periodic muscle paralysis, prolongation of the QT interval with a variety of ventricular arrhythmias (leading to predisposition to sudden cardiac death) and characteristic physical features: short stature, scoliosis, low-set ears, hypertelorism, broad nasal root, micrognathia, clinodactyly, brachydactyly and syndactyly.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008222
- MeSH:D050030
- OMIM:170390
- UMLS:C1563715
- NCIT:C84559
Additional Mondo synonyms (3)
Andersen cardiodysrhythmic periodic paralysis · long QT syndrome 7 · long QT syndrome type 7
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — KCNJ2
- LiteraturePresent
4,262 matched papers (2,844 in last 10 years) Source
- Phenotype characterisedPresent
107 HPO annotations (e.g. Specific learning disability; Toe syndactyly; Bidirectional ventricular ectopy) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (KCNJ2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
107
Associated phenotypes · MONDO:0008222
- Specific learning disability
- Toe syndactyly
- Bidirectional ventricular ectopy
- Delayed skeletal maturation
- Prolonged QTc interval
Showing 5 of 107 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
2
Drugs / clinical candidates · MONDO_0008222
- FLECAINIDE·phase 2
- QUINIDINE·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
4,262
4,262 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
4,262 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,844 in the last 10 years · medium confidence · 91.8th percentile (publications denominator)
Phrase hits: 1,040 · MeSH hits: 0
Who's working on it?
1,108
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Jalife J9 papers · 2026
Department of Internal Medicine and Center for Arrhythmia Research, University of Michigan, Ann Arbor, Michigan, USA jrual@umich.edu jjalife@umich.edu.
Papers in Europe PMC - 02Moreno-Manuel AI8 papers · 2026
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Papers in Europe PMC - 03Gutiérrez LK7 papers · 2026
Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, 28029 Madrid, Spain.
Papers in Europe PMC - 04Hanna MG7 papers · 2023
Centre for Neuromuscular Diseases, QS UCL Institute of Neurology, London, UK.
Papers in Europe PMC - 05Vivekanandam V7 papers · 2024
Centre for Neuromuscular Diseases, QS UCL Institute of Neurology, London, UK.
Papers in Europe PMC - 06Cruz FM6 papers · 2026
Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, 28029 Madrid, Spain.
Papers in Europe PMC - 07Macías Á6 papers · 2026
Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, 28029 Madrid, Spain.
Papers in Europe PMC - 08Martínez-Carrascoso I6 papers · 2026
Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, 28029 Madrid, Spain.
Papers in Europe PMC - 09Totomoch-Serra A6 papers · 2025
Department of Genetics and Molecular Biology, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Mexico City; Doctoral Program in Medical Science, Universidad de la Frontera, Temuco, Chile.
Papers in Europe PMC - 10Vera-Pedrosa ML6 papers · 2026
Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, 28029 Madrid, Spain.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
medium confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06205550·NOT YET RECRUITING·N-of-1 in ATS and MEPPC
Not reviewed·Conditions: Andersen Tawil Syndrome · Multifocal Ectopic Purkinje-related Premature Contractions·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 41 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- ctis·2024-510682-42-01·Authorised, recruiting·Optimal drug therapy for the suppression of ventricular arrhythmias in Andersen-Tawil syndrome and multifocal ectopic Purkinje-related premature contractions: a series of N-of-1 trials
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17701271·Not yet recruiting·129Xenon MRI study of the effects of Mepolizumab on inflammation in the lungs of patients with chronic obstructive pulmonary disease (COPD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78380445·Recruiting·A clinical trial testing a new treatment called mRNA-4194 for people with Lynch syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10930766·Recruiting·Safety, colonisation and immunogenicity following nasal inoculation with genetically modified Neisseria lactamica expressing Factor H binding protein and Neisseria adhesin A - a pilot controlled human infection study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49366748·No longer recruiting·A phase II study to test the safety and effects of BC-006 Injection in adults with obesity
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13720638·Recruiting·Safety and tolerability of APL-3007 administered as a single dose in addition to background therapy with a C5 inhibitor in adults with paroxysmal nocturnal hemoglobinuria
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN42617850·Recruiting·Phase III study of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1-mutated AML
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN24846895·Recruiting·A study to explore the effect of immunotherapy drug, tebentafusp, on patients with clear cell sarcoma (ultra-rare, aggressive type of soft tissue sarcoma that primarily affects young adults)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18283468·No longer recruiting·A clinical trial to learn more about the absorption of radiolabeled drug LXE408, how the body breaks it down, and how quickly the body gets rid of it in healthy men
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22102770·Recruiting·A study to test the safety and effects of a New Drug (LAE103) in healthy people who are overweight or obese, and in healthy postmenopausal women. The study also looks at how LAE103 works when taken alone or together with another drug (LAE102).
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16655785·No longer recruiting·A study in healthy men of the absorption of radiolabelled [14C]LTG-001, how the body breaks it down, and how quickly the body gets rid of it
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10232579·Recruiting·A trial to investigate if psilocybin therapy is effective in improving outcomes for people with opioid use disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10221007·No longer recruiting·A study to compare how the body takes in and gets rid of sefaxersen when given by an injection device or a regular syringe in healthy adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11396451·Enrolling by Invitation·Dietary approaches to the management of polycystic ovary syndrome trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26415952·Recruiting·A Study to evaluate novel KarX and KarT Prototypes versus the KarXT and KarX-EC reference following single doses, and to explore the effect of food after multiple doses of selected prototypes in healthy adult participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73588250·No longer recruiting·The purpose of the trial is to test the safety, tolerability and efficacy of the drug tildacerfont, that is being developed for the treatment of major depressive disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49320109·Recruiting·A CAR T trial for amyloid light chain amyloidosis (AL Amyloid)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18176375·No longer recruiting·A phase 1, safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of a subcutaneous injection of BC-006 in adults with obesity-part 2
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15438979·Recruiting·An early phase trial to test the safety and determine the appropriate dose of BTM-3566 in patients with mature B cell lymphoma and advanced solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN77911445·No longer recruiting·The study is to test the safety and tolerability of a drug called JNJ-39439335, also known as Mavatrep which is being developed for the treatment of pain from osteoarthritis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76681798·No longer recruiting·A research study testing NGM120 in pregnant women with severe nausea and vomiting (Hyperemesis Gravidarum)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99425493·Stopped·A clinical trial exploring a new imaging technique for assessing response to anti-cancer treatments in post-menopausal women with breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65855590·Recruiting·Bivalent vaccination against Salmonella Typhi and Paratyphi A
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15046526·Recruiting·A platform trial for patients with relapsed malignant mesothelioma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN42293056·No longer recruiting·Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and effects of intravenous (IV) and intramuscular (IM) dosing of SPL028 (deuterated DMT fumarate [a serotonergic psychedelic]) in healthy volunteers and participants with major depressive disorder (MDD)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Andersen-Tawil syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Andersen-Tawil syndrome" OR "Andersen syndrome" OR "Long QT syndrome type 7" OR "Andersen cardiodysrhythmic periodic paralysis" OR "long QT syndrome 7") OR ("KCNJ2" OR "KCNJ2 syndrome" OR "KCNJ2-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Andersen-Tawil syndrome" OR "Andersen syndrome" OR "Long QT syndrome type 7" OR "Andersen cardiodysrhythmic periodic paralysis" OR "long QT syndrome 7"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: LQT7
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T23:59:01.263Z
